December 11th, 2017
jobs
homes

Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Emergent BioSolutions Inc. Common Stock (NY:EBS)

7.880 +0.030 (+0.38%)
Streaming Delayed Price Updated: 10:22 AM EDT, Jun 23, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Emergent BioSolutions Inc. Common Stock

< Previous 1 2
...
12 13 14 15 16 17 18 19 Next >
News headline image
NYSE:EBS Investor Notice: Lawsuit Alleges Securities Laws Violations by Emergent BioSolutions Inc ↗
San Diego, CA -- (SBWIRE) -- 05/04/2021 -- An investor, who purchased NYSE:EBS shares, filed a lawsuit against Emergent BioSolutions Inc over alleged violations of Federal Securities Laws. 
Via SBWire
Topics Lawsuit
News headline image
SHAREHOLDER ACTION NOTICE: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against Emergent BioSolutions Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Lawsuit
News headline image
Is Emergent BioSolutions Still a Buy After Its Coronavirus Vaccine Flub? ↗
Shareholders beware: The hits just won't stop coming. 
Via The Motley Fool
News headline image
SHAREHOLDER ACTION REMINDER: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against Emergent BioSolutions Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Lawsuit
News headline image
SHAREHOLDER ALERT: Law Offices of Timothy L. Miles Announces Emergent BioSolutions Inc. (EBS) Sued by Shareholders
SHAREHOLDER ALERT: The Law Offices of Timothy L. Miles Announces That Emergent BioSolutions Inc. (EBS) is Being Sued for Misleading Shareholders 
Via EIN Presswire
Topics Lawsuit
News headline image
Emergent BioSolutions Has Supply Of 60M Johnson & Johnson COVID-19 Vaccine Doses Awaiting Approval: Bloomberg ↗
Emergent BioSolutions Inc has manufactured over 115 million doses of the drug substance used in the Johnson & Johnson COVID-19 vaccine, 60 million doses of which are in vials and ready to deploy at... 
Via Talk Markets
News headline image
Emergent BioSolutions Has Supply Of 60M Johnson & Johnson COVID-19 Vaccine Doses Awaiting Approval: Bloomberg ↗
Emergent BioSolutions Inc (NYSE: EBS) has manufactured over 115 million doses of drug substance used in the Johnson & Johnson (NYSE: JNJ) COVID-19... 
Via Benzinga
News headline image
SHAREHOLDER ACTION ALERT: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against Emergent BioSolutions Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Lawsuit
News headline image
Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Emergent BioSolutions Inc. (EBS)
From Glancy Prongay & Murray LLP
Via Business Wire
News headline image
Emergent BioSolutions Hopeful To Restart Vaccine Production, Plans To Submit Response To FDA Within Days ↗
Emergent BioSolutions Inc (NYSE: EBS) said it hopes to respond to U.S. regulators within days on how to resolve the problems at its Baltimore plant, which have forced... 
Via Benzinga
News headline image
EMERGENT INVESTORS: June 18, 2021 Filing Deadline in Class Action – Contact Lieff Cabraser
From Lieff Cabraser Heimann & Bernstein, LLP
Via Business Wire
News headline image
The Daily Biotech Pulse: Hyperphosphatemia Drug Regulatory Review Extended, Phathom Pharma Data Readout, 2 IPOs ↗
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 29) AtriCure, Inc. (NASDAQ:... 
Via Benzinga
News headline image
Emergent BioSolutions Inc (EBS) Q1 2021 Earnings Call Transcript ↗
EBS earnings call for the period ending March 31, 2021. 
Via The Motley Fool
Topics Earnings
News headline image
Emergent BioSolutions: Q1 Earnings Insights ↗
Shares of Emergent BioSolutions (NYSE:EBS) decreased in after-market trading after the company reported Q1 results. Quarterly Results Earnings per share rose 15200.00% over the... 
Via Benzinga
News headline image
INVESTOR ACTION NOTICE: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against Emergent BioSolutions Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Lawsuit
News headline image
EBS Investor Alert: Bronstein, Gewirtz & Grossman, LLC Reminds Emergent BioSolutions Inc. Investors of Class Action and Encourages Investors to Contact the Firm
From Bronstein, Gewirtz & Grossman, LLC
Via Business Wire
News headline image
EMERGENT SHAREHOLDERS: June 18, 2021 Filing Deadline in Class Action – Contact Lieff Cabraser
From Lieff Cabraser Heimann & Bernstein, LLP
Via Business Wire
News headline image
The Daily Biotech Pulse: Clinical Setback For Adverum, Galera Posts Data Readout, Moderna To Invest In Vaccine Manufacturing, Decision Day For Ardelyx ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 28) Axonics, Inc. (NASDAQ:... 
Via Benzinga
News headline image
INVESTOR ACTION REMINDER: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against Emergent BioSolutions Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Lawsuit
News headline image
Deadline Reminder: Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Emergent BioSolutions Inc. (EBS)
From Law Offices of Howard G. Smith
Via Business Wire
News headline image
A Preview Of Emergent BioSolutions's Earnings ↗
Emergent BioSolutions (NYSE:EBS) announces its next round of earnings this Thursday, April 29. Here is Benzinga's everything-that-matters guide for this Thursday's Q1 earnings... 
Via Benzinga
News headline image
ROSEN, A TOP RANKED LAW FIRM, Encourages Emergent BioSolutions Inc. Investors with Losses to Secure Counsel Before Important Deadline – EBS
From The Rosen Law Firm, P.A.
Via Business Wire
News headline image
INVESTOR ACTION ALERT: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against Emergent BioSolutions Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Lawsuit
News headline image
INVESTOR ALERT: Scott+Scott Attorneys at Law LLP Investigates Emergent BioSolutions Inc.’s Directors and Officers for Breach of Fiduciary Duties – EBS
From Scott+Scott Attorneys at Law LLP
Via Business Wire
News headline image
The Law Offices of Frank R. Cruz Announces the Filing of a Securities Class Action on Behalf of Emergent BioSolutions Inc. (EBS) Investors
From The Law Offices of Frank R. Cruz
Via Business Wire
News headline image
Is There Any Hope Left for Emergent BioSolutions? ↗
The go-to government contractor is in deep trouble. Should investors buy the dip? 
Via The Motley Fool
News headline image
EBS INVESTOR ALERT: Bernstein Liebhard LLP Announces that a Securities Class Action Lawsuit Has Been Filed Against Emergent BioSolutions Inc.
NEW YORK, NY / ACCESSWIRE / April 26, 2021 / Bernstein Liebhard, a nationally acclaimed investor rights law firm, announces that a securities class action lawsuit has been filed on behalf of investors... 
From Bernstein Liebhard LLP
Via AccessWire
Topics Lawsuit
News headline image
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces the Filing of a Securities Class Action on Behalf of Emergent BioSolutions Inc. (EBS) Investors
From Glancy Prongay & Murray LLP
Via Business Wire
News headline image
SHAREHOLDER ALERT: Robbins LLP Announces That Emergent BioSolutions Inc. (EBS) is Being Sued for Misleading Shareholders
From Robbins LLP
Via Business Wire
News headline image
The Week Ahead In Biotech (April 25-May 1): FDA Decisions For Sol-Gel, Protalix Bio, Ardelyx ↗
Biopharma stocks came back from the weakness seen in the first two sessions to close the week ended April 23 higher. Johnson & Johnson (NYSE: JNJ) and Roche Holding AG (OTC:... 
Via Benzinga
< Previous 1 2
...
12 13 14 15 16 17 18 19 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

More ways to get to us

Lethbridge Herald Facebook Facebook
Lethbridge Herald Twitter Twitter
Lethbridge Herald YouTube YouTube

About Us

Contact the Lethbridge Herald

504 - 7th Street South
Lethbridge, AB T1J 3Z7

[P] (403) 328-4411
[F] (403)328-4536

Print Advertising: (403) 328-4410
National Advertising: (403) 380-7585
Online Advertising: (403) 380-7585
Classifieds: (403) 328-4433

© 1996-2017 The Lethbridge Herald, A Division of Continental Newspapers Canada Ltd.